PUBLIC POLICY
ASM Policy efforts focus on communicating the importance of the microbial science to Congress, Federal Agencies and the Public.

The ASM submitted funding recommendations for the National Institutes of Health for FY 2018 to Congress. 

The ASM submitted funding recommendations for the Centers for Disease Control and Prevention for FY 2018 to Congress. 

Thursday, 23 February 2017 12:24

Public Policy Brief - February 23, 2017

The ASM sent a letter to Senator Lamar Alexander (R-TN), chair and Senator Patty Murray (D-WA), ranking member of the Senate's health committee and Representative Greg Walden (R-OR), chair and Representative Frank Pallone Jr. (D-NJ), ranking member of the House Energy & Commerce Committee, and Texas Reps. Michael Burgess (R) and Gene Green (D), chairman and ranking member of the subcommittee on health regarding their “Dear Colleague” letter to their colleagues highlighting the benefits of vaccines.

Wednesday, 22 February 2017 10:15

Public Policy Brief - February 22, 2017

Effective October 2016, the Centers for Disease Control and Prevention added Bacillus cereus biovar anthracis as a Tier 1 select agent to the list of select agents and toxins. Sentinel laboratories should continue using the existing ASM Sentinel Level Clinical Laboratory Guidelines for Suspected Agents of Bioterrorism and Emerging Infectious Diseases, Bacillus anthracis with new recommendations suggested here.  

Thursday, 09 February 2017 12:59

Coalition Letter Supporting Biomedical Research

The ASM signed onto a letter to President Trump and Congressional leadership, urging the completion of an FY 2017 spending package that includes $34.1 billion for the National Institutes of Health (NIH). The letter was signed by 260 patient, medical, scientific, academic, and research organizations.

Wednesday, 08 February 2017 14:45

Public Policy Daily Brief – February 8, 2017

Tuesday, 07 February 2017 13:54

Coalition Letter Supporting Vaccine Safety

The ASM joined over 350 organizations in a letter to President Donald Trump expressing support for the safety of vaccines. 

Wednesday, 01 February 2017 11:25

Public Policy Daily Brief - February 1, 2017

On January 31, the ASM sent a letter to the president regarding the potential consequences travel bans could have on both U.S. and global scientific communities.

On January 13 the ASM signed on to a letter with 48 other organizations to President Trump.  The letter urged more funding for antimicrobial resistance research and development.

The ASM sent a letter supporting the safety and efficacy of vaccines to President-elect Trump and offered scientific guidance to the new Administration. 

The White House Office of Science and Technology Policy (OSTP) released, “Recommended Policy Guidance for Departmental Development of Review Mechanisms for Potential Pandemic Pathogen Care and Oversight (P3CO).”

TPL_asm2013_ADDITIONAL_INFORMATION

TPL_asm2013_SEARCH